Genmab A+s

H. Lundbeck A/s

Arnout F Gerritsen

Paul Parren

Jan G J Van De Winkel

Marcus A Van Dijk

Janine Schuurman

Ole Baadsgaard

Edward Norbert Van Den Brink

Søren Christensen

Rob N De Jong

Ibrahim John Malik

Jeffrey B Stavenhagen

Jan Egebjerg

Lars Christian Biilmann Rønn

Jørgen Petersen

Edward L Halk

Aran Frank Labrijn

Joost J Neijssen

Joyce Meesters

Patrick Van Berkel

Ewald T J Van Den Bremer

Michael J Gramer

Amitava Kundu

Werner L Vos

Patrick Priem

Muriel Van Kampen

Jan Van De Winkel

Yvo Graus

Martin John Glennie

Jessica Teeling

Jorgen Petersen

Richard Hibbert

Sigrid Ruuls

Mischa Houtkamp

Jørgen Peterson

Tina Stummann

Marcus Antonius Van Dijk

Joyce I Meesters

Ewald TJ Van Den Bremer

Adinda Van Poucke

Martijn Bosch

The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Agent, uses and methods for treatment

The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.

Method for producing a controlled mixture of two or more different antibodies

The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

The present invention relates to an in vitro method for production of heterodimeric proteins.

Production of heterodimeric proteins

The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).

Agents, uses and methods for treatment

Anti-sortilin antibodies, uses and methods for treatment

Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human monoclonal antibodies to epidermal growth factor receptor (EGFR)

Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human monoclonal antibodies against CD20

Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Method for treating psoriasis by administering human antibodies specific for Interleukin 15 (IL-15)

Nucleic acid encoding human antibodies specific for interleukin 15 (IL-15)

Growing community of inventors

Bunnik, Netherlands

Arnout F Gerritsen